| Autor: |
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo-Jack, Nathaniel J. Myall, Georg Richtig, Jillian W.P. Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R. Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A. Sosman, Scott Kopetz, Vivek Subbiah, Michael A. Davies, Anna L. Groover, Ryan J. Sullivan, Keith T. Flaherty, Douglas B. Johnson, Andrea Benedetti, David W. Cescon, Anna Spreafico, George Zogopoulos, April A.N. Rose |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
JCO precision oncology. 6 |
| ISSN: |
2473-4284 |
| Popis: |
PURPOSE Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to molecular characteristics. Consensus treatment strategies for class 2 and 3 BRAF mutations have not yet been established. METHODS We performed a systematic review and meta-analysis with published reports of individual patients with cancer harboring class 2 or 3 BRAF mutations from 2010 to 2021, to assess treatment outcomes with US Food and Drug Administration–approved mitogen-activated protein kinase (MAPK) pathway targeted therapy (MAPK TT) according to BRAF class, cancer type, and MAPK TT type. Coprimary outcomes were response rate and progression-free survival. RESULTS A total of 18,167 studies were screened, identifying 80 studies with 238 patients who met inclusion criteria. This included 167 patients with class 2 and 71 patients with class 3 BRAF mutations. Overall, 77 patients achieved a treatment response. In both univariate and multivariable analyses, response rate and progression-free survival were higher among patients with class 2 compared with class 3 mutations, findings that remain when analyses are restricted to patients with melanoma or lung primary cancers. MEK ± BRAF inhibitors demonstrated greater clinical activity in class 2 compared with class 3 BRAF-mutant tumors than BRAF or EGFR inhibitors. CONCLUSION This meta-analysis suggests that MAPK TTs have clinical activity in some class 2 and 3 BRAF-mutant cancers. BRAF class may dictate responsiveness to current and emerging treatment strategies, particularly in melanoma and lung cancers. Together, this analysis provides clinical validation of predictions made on the basis of a mutation classification system established in the preclinical literature. Further evaluation with prospective clinical trials is needed for this population. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
